Gene: WNT2B

7482
WNT13
Wnt family member 2B
protein-coding
1p13.2
Ensembl:ENSG00000134245 MIM:601968 Vega:OTTHUMG00000011157 UniprotKB:Q93097
NG_052953.1
PubMed
0   ANCO-SNPs
ND
1   
8.916e-1 (AD)  8.155e-1 (ND)   (Frontal_Cortex)
4.820e-1 (AD)  6.920e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg25320499chr1:113052563WNT2BGene body3.010e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
REV10.773
ZNF3180.769
DDI20.763
EPG50.762
ZNF4400.762
MAP3K30.76
APAF10.76
MEF2A0.76
SETDB20.757
KRIT10.756

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
S100A1-0.394
PLA2G5-0.39
DIO2-0.376
RBP1-0.365
ENDOU-0.359
PYGM-0.356
WNT7B-0.35
HPSE2-0.341
BTBD17-0.339
TNNT1-0.337

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of WNT2B mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of WNT2B mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of WNT2B mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of WNT2B mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of WNT2B mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT2B mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT2B mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of WNT2B mRNA26690555
D000082Acetaminophen[Clofibrate co-treated with Acetaminophen] affects the expression of WNT2B mRNA17585979
D000082AcetaminophenPPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of WNT2B mRNA]17585979
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of WNT2B gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of WNT2B mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of WNT2B mRNA24449571
D001149Arsenates[Atrazine co-treated with Arsenates] results in increased expression of WNT2B mRNA18585445
D001151ArsenicArsenic affects the methylation of WNT2B gene25304211
D001280Atrazine[Atrazine co-treated with Arsenates] results in increased expression of WNT2B mRNA18585445
D019324beta-Naphthoflavone[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of WNT2B mRNA18164116
C543008bis(4-hydroxyphenyl)sulfonebis(4-hydroxyphenyl)sulfone results in increased expression of WNT2B mRNA27685785
C006780bisphenol Abisphenol A results in increased methylation of WNT2B promoter27312807
C006780bisphenol Abisphenol A results in decreased expression of WNT2B mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of WNT2B gene28505145
D004390ChlorpyrifosChlorpyrifos results in increased expression of WNT2B mRNA18502319
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of WNT2B gene20938992
D002994Clofibrate[Clofibrate co-treated with Acetaminophen] affects the expression of WNT2B mRNA17585979
D002994ClofibratePPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of WNT2B mRNA]17585979
C107676deguelindeguelin results in decreased expression of WNT2B mRNA19861542
D003976DiazinonDiazinon affects the expression of WNT2B mRNA19130878
D003976DiazinonDiazinon results in increased expression of WNT2B mRNA18502319
D004026DieldrinDieldrin results in decreased expression of WNT2B mRNA19130878
D004052Diethylnitrosamine[Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of WNT2B mRNA18164116
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of WNT2B mRNA19371625
C118739entinostatentinostat results in increased expression of WNT2B mRNA27188386
D005419FlavonoidsFlavonoids results in decreased expression of WNT2B mRNA18035473
D005492Folic Acid[Folic Acid co-treated with sodium arsenite] results in decreased methylation of WNT2B mRNA22959928
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of WNT2B gene20938992
C039281furanfuran results in increased expression of WNT2B mRNA27387713
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of WNT2B mRNA26752646
D007657Ketone BodiesKetone Bodies results in decreased expression of WNT2B mRNA16807920
D015122MercaptopurineMercaptopurine results in decreased expression of WNT2B mRNA23358152
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of WNT2B gene20938992
D008727MethotrexateMethotrexate affects the expression of WNT2B mRNA18502557
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of WNT2B mRNA28001369
D009532NickelNickel results in decreased expression of WNT2B mRNA25583101
D009532NickelNickel results in decreased expression of WNT2B mRNA19130878
D009534NiclosamideNiclosamide results in decreased expression of WNT2B mRNA22576131
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of WNT2B mRNA27935865
C572573N-nitroso-tris-chloroethylurea[N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of WNT2B mRNA27935865
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of WNT2B mRNA"25510870
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT2B mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of WNT2B mRNA26272509
C060836pioglitazone[N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of WNT2B mRNA27935865
C005556propionaldehydepropionaldehyde results in increased expression of WNT2B mRNA26079696
D011441PropylthiouracilPropylthiouracil results in decreased expression of WNT2B mRNA24780913
C017947sodium arsenite[Folic Acid co-treated with sodium arsenite] results in decreased methylation of WNT2B mRNA22959928
D014212TretinoinTretinoin results in increased expression of WNT2B mRNA16790478
C012589trichostatin Atrichostatin A results in decreased expression of WNT2B mRNA24935251
D014635Valproic AcidValproic Acid affects the expression of WNT2B mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of WNT2B mRNA23527032
D014635Valproic AcidValproic Acid results in increased expression of WNT2B mRNA23179753|2519280
C581157XL147[N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of WNT2B mRNA27935865

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005109frizzled binding-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0002062chondrocyte differentiation-IEP15135146  
GO:0002088lens development in camera-type eye-ISS16258938  
GO:0008584male gonad development-IEP17848411  
GO:0009267cellular response to starvation-IEA-  
GO:0016055Wnt signaling pathway-IBA21873635  
GO:0016055Wnt signaling pathway-IMP15135146  
GO:0016055Wnt signaling pathway-TAS-  
GO:0021871forebrain regionalization-IEP15164427  
GO:0030182neuron differentiation-IBA21873635  
GO:0030182neuron differentiation-ISS-  
GO:0045165cell fate commitment-IBA21873635  
GO:0060070canonical Wnt signaling pathway-IEA-  
GO:0060492lung induction-IEA-  
GO:0060638mesenchymal-epithelial cell signaling-IEA-  
GO:0061072iris morphogenesis-ISS16258938  
GO:0061303cornea development in camera-type eye-ISS16258938  
GO:0071425hematopoietic stem cell proliferation-IDA9787155  
GO:0090190positive regulation of branching involved in ureteric bud morphogenesis-IEA-  
GO:0090263positive regulation of canonical Wnt signaling pathway-IDA11741304  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS-  
GO:0005615extracellular space-IBA21873635  
GO:0005615extracellular space-NAS15135146  
GO:0043231intracellular membrane-bounded organelle-IDA-  
KEGG ID KEGG Term
hsa04310Wnt signaling pathway
hsa04340Hedgehog signaling pathway
hsa04916Melanogenesis
hsa05200Pathways in cancer
hsa05217Basal cell carcinoma
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionTAS
R-HSA-162582Signal TransductionIEA
R-HSA-195721Signaling by WNTTAS
R-HSA-195721Signaling by WNTIEA
R-HSA-3238698WNT ligand biogenesis and traffickingTAS
R-HSA-3238698WNT ligand biogenesis and traffickingIEA
R-HSA-372790Signaling by GPCRIEA
R-HSA-373080Class B/2 (Secretin family receptors)IEA
R-HSA-500792GPCR ligand bindingIEA

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
29162857Temporal expression pattern of genes during the period of sex differentiation in human embryonic gonads. (2017 Nov 21)Mamsen LSSci Rep